Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin

Journal of Lipid Research

Volumn 40, Issue 6, 1999, Pages 1078-1089

  Wilcox, Lisa J ^a,b,d   Hugh, P ^b,d   Barrett, R ^b,c,d   Huff, Murray W ^a,b,d  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Department of Bioengineering ^*  (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ApoB; Atorvastatin; Cholesterol synthesis; HepG2 cells; HMG CoA reductase inhibitor; Simvastatin

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CELL CULTURE; CHOLESTEROL SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ESTERIFICATION; HUMAN; HUMAN CELL; LIPOGENESIS; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

APOLIPOPROTEINS B; CARRIER PROTEINS; CELL LINE; CHOLESTEROL ESTERS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LIPOPROTEINS; LIVER; PYRROLES; RECEPTORS, LDL; RNA, MESSENGER; SIMVASTATIN;

EID: 0344759107     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Chan, L. 1992. Apolipoprotein B, the major protein component of triglyceride rich and low density lipoprotein. J. Biol. Chem. 267: 25621-25624.
2. Sigurdsson, G., A. Nicholl, and B. Lewis. 1975. Conversion of very low density lipoprotein to low density lipoprotein: a metabolic study of apolipoprotein B catabolism in man. J. Clin. Invest. 56: 1481-1490.
3. Sakata, N., X. Wu, J. Dixon, and H. N. Ginsberg. 1993. Proteolysis and lipid-facilitated translocation are distinct but competitive processes that regulate secretion of apolipoprotein B in HepG2 cells. J. Biol. Chem. 268: 22967-22970.
4. Du, E. Z., J. Kurth, S. Wang, P. Humiston, and R. A. Davis. 1994. Proteolysis-coupled secretion of the N-terminus of apolipoprotein B. Characterization of a transient, translocation arrested intermediate. J. Biol. Chem. 269: 24169-24176.
5. Pullinger, C. R., J. D. North, B. Teng, V. A. Rifici, A. E. Ronhild de Brito, and J. Scott. 1989. The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J. Lipid Res. 30: 1065-1077.
6. Wu, X., N. Sakata, J. Dixon, and H. N. Ginsberg. 1994. Exogenous VLDL stimulates apolipoprotein B secretion from HepG2 cells by both pre-and post-translational mechanisms. J. Lipid Res. 35: 1200-1210.
7. Furukawa, S., and T. Hirano. 1993. Rapid stimulation of apolipoprotein B secretion by oleate is not associated with cholesteryl ester biosynthesis in HepG2 cells. Biochim. Biophys. Acta. 1170: 32-37.
8. Wu, X., N. Sakata, E. Lui, and H. N. Ginsberg. 1994. Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells by cholesteryl ester. J. Biol. Chem. 269: 12375-12382.
9. Benoist, F., and T. Grand-Perret. 1996. ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools. Arterioscler. Thromb. Vasc. Biol. 16: 1229-1235.
10. Yao, Z., and D. E. Vance. 1988. The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J. Biol. Chem. 263: 2998-3004.
11. Musanti, R., L. Giorgini, P. Lovisolo, A. Pirillo, A. Chiari, and G. Ghiselli. 1996. Inhibition of acyl-CoA:cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. J. Lipid Res. 37: 1-14.
12. Tanaka, M., H. Jingami, H. Otani, M. Cho, Y. Ueda, H. Arai, Y. Nagano, T. Doi, M. Yokode, and T. Kita. 1993. Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes. J. BioL Chem. 268: 12713-12718.
13. Cianflone, K., Z. Yasruel, M. A. Rodriguez, D. Vas, and A. D. Sniderman. 1990. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J. Lipid Res. 31: 2045-2055.
14. Kohen Avramoglu, R., K. Cianflone, and A. D. Sniderman. 1995. Role of the neutral lipid accessible pool in the regulation of secretion of apoB-100 lipoprotein particles by HepG2 cells. J. Lipid Res. 36: 2513-2528.
15. Qin, W., J. Infante, S. Wang, and R. Infante. 1992. Regulation of HMG-CoA reductase, apolipoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in HepG2, human and rat hepatocytes. Biochim. Biophys. Acta. 1127: 57-66.
16. Dashti, N. 1992. The effect of low density lipoproteins, cholesterol, and 25-hydroxycholesterol on apolipoprotein B gene expression in HepG2 cells. J. Biol Chem. 267: 7160-7169.
17. Carr, T. P., J. R. L. Hamilton, and L. L. Rudel. 1995. ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J. Lipid Res. 36: 25-36.
18. Huff, M. W., D. E. Telford, P. H. Barrett, D. W. Bilheimer, and P. J. Gillies. 1994. Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet. Arterioscler. Thromb. 14: 1498-1508.
19. Arad, Y., R. Ramakrishnan, and H. N. Ginsberg. 1992. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism. 41: 487-493.
20. Burnett, J. R., L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff. 1997. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler. Thromb. Vasc. Biol. 17: 2589-2600.
21. Watts, G. F., M. H. Cummings, M. Umpleby, J. R. Quiney, R. Naoumova, G. R. Thompson, and P. H. Sonksen. 1995. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolemia: pathophysiological and therapeutic implications. Eur. J. Clin. Invest. 25: 559-567.
22. Watts, G. F., R. P. Naoumova, J. M. Kelly, F. M. Riches, K. D. Croft, and G. R. Thompson. 1997. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am. J. Physiol 273: E462-E470.
23. Sato, R., T. Imanaka, and T. Takano. 1990. The effect of HMG-CoA reductase inhibitor (CS-514) on the synthesis and secretion of apolipoproteins B and A-I in the human hepatoblastoma HepG2. Biochim. Biophys. Acta. 1042: 36-41.
24. Brown, M. S., and J. L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232: 34-47.
25. Bilheimer, D. W., S. M. Grundy, M. S. Brown, and J. L. Goldstein. 1983. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. USA. 80: 4124-4128.
26. Huff, M. W., D. E. Telford, K. Woodcroft, and W. L. P. Strong. 1985. Mevinolin and cholestyramine inhibit the direct synthesis of low density lipoprotein apolipoprotein B in miniature pigs. J. Lipid Res. 26: 1175-1186.
27. Black, D. M. 1995. Atorvastatin: a step ahead for HMG-CoA reductase inhibitors. In Atherosclerosis X. F. P. Woodward, J. Davignon, and A. Sniderman, editors. Elsevier Science Publishers BV, Amsterdam. 307-310.
28. Dart, A., G. Jerums, G. Nicholson, M. d'Emden, I. Hamilton-Craig, G. Tallis, J. Best, M. West, D. Sullivan, P. Bracs, and D. Black. 1997. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am. J. Cardiol. 80: 39-44.
29. Jones, P., S. Kafonek, I. Laurora, and D. Hunninghake. 1998. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 81: 582-587.
30. Krause, B. R., and R. S. Newton. 1995. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis. 117: 237-244.
31. Bisgaier, C. L., A. D. Essenburg, B. J. Auerbach, M. E. Pape, C. S. Sekerke, A. Gee, S. Wolle, and R. S. Newton. 1997. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J. Lipid Res. 38: 2502-2515.
32. Evans, A. J., C. G. Sawyez, B. M. Wolfe, and M. W. Huff. 1992. Lipolysis is a prerequisite for lipid accumulation in HepG2 cells induced by large hypertriglyceridemic very low density lipoproteins. J. Biol. Chem. 267: 10743-10751.
33. Carr, T. P., C. J. Andresen, and L. L. Rudel. 1993. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin. Biochem. 26: 39-42.
34. Whitman, S. C., C. G. Sawyez, D. B. Miller, B. M. Wolfe, and M. W. Huff. 1998. Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macrophage cholesteryl ester accumulation than oxidized LDL. J. Lipid Res. 39: 1008-1020.
35. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
36. Adeli, K. 1994. Regulated intracellular degradation of apolipoprotein B in semipermeable HepG2 cells. J. Biol. Chem. 269: 9166-9175.
37. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227: 680-685.
38. Azrolan, N., and J. L. Breslow. 1990. A solution hybridization/ RNase protection assay with riboprobes to determine absolute levels of apoB, A-I, and E mRNA in human hepatoma cell lines. J. Lipid Res. 31: 1141-1146.
39. Tam, S., T. K. Archer, and R. G. Deeley. 1985. Effects of estrogen on apolipoprotein secretion by the human hepatocarcinoma cell line, HepG2. J. Biol. Chem. 260: 1670-1675.
40. Ness, G. C., C. M. Chambers, and D. Lopez. 1998. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity. J. Lipid Res. 39: 75-84.
41. Naoumova, R. P., S. Dunn, L. Rallidis, O. Abu-Muhana, C. Neuwirth, N. B. Rendell, G. W. Taylor, and G. R. Thompson. 1997. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J. Lipid Res. 38: 1496-1500.
42. Bergstrom, J. D., R. G. Bostedor, D. J. Rew, W. M. Geissler, S. D. Wright, and Y. S. Chao. 1998. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Biochim. Biophys. Acta. 1389: 213-221.
43. Mohammadi, A., J. Macri, R. Newton, T. Romain, D. Dulay, and K. Adeli. 1998. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler. Thromb. Vasc. Biol. 18: 783-793.
44. Conde, K., V. Marcela, B. R. Krause, R. S. Newton, and M. L. Fernandez. 1996. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J. Lipid Res. 37: 2372-2382.
45. Graham, A., J. L. Wood, and L. J. Russell. 1996. Cholesterol esterification is not essential for secretion of lipoprotein components by HepG2 cells. Biochim. Biophys. Acta. 1302: 46-54.
46. Wu, X., A. Shang, H. Jiang, and H. N. Ginsberg. 1996. Low rates of apoB secretion from HepG2 cells result from reduced delivery of newly synthesized triglyceride to a "secretion-coupled" pool. J. Lipid Res. 37: 1198-1206.
47. Gibbons, G. F., R. Khurana, A. Odwell, and M. C. L. Seelaender. 1994. Lipid balance in HepG2 cells: active synthesis and impaired mobilization. J. Lipid Res. 35: 1801-1808.
48. Burnett, J. R., L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff. 1999. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J. Lipid Res. In press.
49. Bostrom, K., M. Wettesten, J. Boren, G. Bondjers, O. Wiklund, and S. Olofsson. 1986. Pulse-chase studies of the synthesis and intracellular transport of apolipoprotein B-100 in HepG2 cells. J. Biol. Chem. 261: 13800-13806.
50. Ginsberg, H. N. 1997. Role of lipid synthesis, chaperone proteins and proteasomes in the assembly and secretion of apoprotein B-containing lipoproteins from cultured liver cells. Clin. Exp. Pharmacol. Physiol. 24: A29-A32.
51. Yeung, S. J., S. H. Chen, and L. Chan. 1996. Ubiquitin-proteasome pathway mediates intracellular degradation of apolipoprotein B. Biochemistry. 35: 843-848.
52. Fisher, E. A., M. Zhou, D. M. Mitchell, X. Wu, S. Omura, H. Wang, A. L. Goldberg, and H. N. Ginsberg. 1997. The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70. J. Biol. Chem. 272: 20427-20434.
53. Wu, X. J., N. Sakata, K. M. Lele, M. Y. Zhou, H. S. Jiang, and H. N. Ginsberg. 1997. A two-site model for apoB degradation in HepG2 cells. J. Biol. Chem. 272: 11575-11580.
54. Adeli, K., J. Macri. A. Mohammadi, M. Kito, R. Urade, and D. Cavallo. 1997. Apolipoprotein B is intracellularly associated with an ER-60 protease homologue in HepG2 cells. J. Biol. Chem. 272: 22489-22494.
55. Wetterau, J. R., L. P. Aggerbeck, M. Bouma, C. Eisenberg, A. Munck, M. Hermier, J. Schmitz, G. Gay, D. J. Rader, and G. E. Richard. 1992. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 258: 999-1001.
56. Jamil, H., J. K. Dickson, Jr., C. Chu, M. W. Lago, J. K. Rinehart, S. A. Biller, R. E. Gregg, and J. R. Wetterau. 1995. Microsomal triglyceride transfer protein: specificity of lipid binding and transport. J. Biol. Chem. 270: 6549-6554.
57. Lin, M. C. M., D. Gordon, and J. R. Wetterau. 1995. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J. Lipid Res. 36: 1073-1081.